Studies on serotonergic markers in the human hippocampus: changes in subjects with bipolar disorder.
BACKGROUND
Various studies suggest the hippocampus and serotonergic systems are important in the pathology of bipolar disorder (BD). We therefore measured hippocampal serotonergic markers in post-mortem tissue from BD and control subjects.


METHODS
The density and affinity of [3H]citalopram binding to the serotonin transporter (SERT), as well as the density of the 5HT(2A), 5HT(1A), 5HT(1D) and 5HT(1F) receptors were measured.


RESULTS
The density of SERT and 5HT receptors was no different in BD. There was a significant decrease in the affinity of [3H]citalopram binding to SERT in the stratum lacunosum-moleculare (S(lac)) in BD (K(d) mean+/-S.E.M.=4.3+/-0.8 vs. 1.9+/-0.3 nM).


CONCLUSIONS
This study was completed using relatively small cohorts.


CONCLUSIONS
There are no generalised changes in hippocampal serotonergic markers in the hippocampus from subjects with BD. There is a decreased affinity of radioligand binding to S(lac) SERT in subjects with BD.
Dean
Brian
B
The Rebecca L. Cooper Research Laboratories, The Mental Health Research Institute of Victoria, Parkville, Victoria, Australia. b.dean@papyrus.mhri.edu.au
Scarr
Elizabeth
E
Pavey
Geoffrey
G
Copolov
David
D
D000345:Affinity Labels / Q000493:pharmacokinetics; D001665:Binding Sites; D015415:Biomarkers; D001714:Bipolar Disorder / Q000378:metabolism* / Q000473:pathology*; D002352:Carrier Proteins / Q000378:metabolism; D002452:Cell Count; D015283:Citalopram / Q000493:pharmacokinetics*; D046508:Culture Techniques; D006624:Hippocampus / Q000378:metabolism* / Q000473:pathology*; D006801:Humans; D007650:Ketanserin / Q000493:pharmacokinetics; D008562:Membrane Glycoproteins / Q000378:metabolism; D026901:Membrane Transport Proteins; D009419:Nerve Tissue Proteins; D011985:Receptors, Serotonin / Q000378:metabolism*; D012702:Serotonin Antagonists / Q000493:pharmacokinetics; D050486:Serotonin Plasma Membrane Transport Proteins; D017366:Serotonin Receptor Agonists / Q000493:pharmacokinetics; D017367:Selective Serotonin Reuptake Inhibitors / Q000493:pharmacokinetics*; D018170:Sumatriptan / Q000493:pharmacokinetics
D000345:Affinity Labels; D015415:Biomarkers; D002352:Carrier Proteins; D015283:Citalopram; D007650:Ketanserin; D008562:Membrane Glycoproteins; D026901:Membrane Transport Proteins; D009419:Nerve Tissue Proteins; D011985:Receptors, Serotonin; D012702:Serotonin Antagonists; D050486:Serotonin Plasma Membrane Transport Proteins; D017366:Serotonin Receptor Agonists; D017367:Selective Serotonin Reuptake Inhibitors; D018170:Sumatriptan; C493230:SLC6A4 protein, human